Clinical Trial Update: Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating pembrolizumab plus docetaxel for recurrent or metastatic head and neck cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Medical University of Vienna | Conditions: Head and Neck Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-12-04